Journal
ADVANCED DRUG DELIVERY REVIEWS
Volume 61, Issue 7-8, Pages 542-553Publisher
ELSEVIER
DOI: 10.1016/j.addr.2009.02.006
Keywords
Cancer; Angiogenesis; Promoter; Tumor microenvironment; Review
Categories
Funding
- NIH/NCI [P50-CA97248]
- NIH/NIDCR [R01-DE14601, R01-DE15948, R01-DE16586, R21-DE19279]
Ask authors/readers for more resources
It is well known that angiogenesis plays a critical role in the pathobiology of tumors. Recent clinical trials have shown that inhibition of angiogenesis can be an effective therapeutic strategy for patients with cancer. However, one of the outstanding issues in anti-angiogenic treatment for cancer is the development of toxicities related to off-target effects of drugs. Transcriptional targeting of tumor endothelial cells involves the use of specific promoters for selective expression of therapeutic genes in the endothelial cells lining the blood vessels of tumors. Recently, several genes that are expressed specifically in tumor-associated endothelial cells have been identified and characterized. These discoveries have enhanced the prospectus of transcriptionally targeting tumor endothelial cells for cancer gene therapy. In this manuscript, we review the promoters, vectors, and therapeutic genes that have been used for transcriptional targeting of tumor endothelial cells, and discuss the prospects of such approaches for cancer gene therapy. (C) 2009 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available